Brooks Laboratories Limited
NSE: BROOKS BSE: BROOKS
Prev Close
148.95
Open Price
145.97
Volume
12,621
Today Low / High
145.97 / 146.14
52 WK Low / High
82 / 198.86
Range
139 - 153
Prev Close
149
Open Price
147.95
Volume
1,215
Today Low / High
146.05 / 147.95
52 WK Low / High
82.25 / 202.8
Range
139 - 153
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 145.97 (target range: 139 - 153), reflecting a change of -2.98 (-2.00067%). On the BSE, it is listed at 146.05 (target range: 139 - 153), showing a change of -2.95 (-1.97987%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Brooks Laboratories Limited Graph
Brooks Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Brooks Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 145.97, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 146.05 | 147.51 | 132.76 - 162.26 |
148.97 | 119.18 - 178.77 | ||
150.43 | 105.30 - 195.56 | ||
Bearish Scenario | 146.05 | 144.59 | 130.13 - 159.05 |
143.13 | 114.50 - 171.75 | ||
141.67 | 99.17 - 184.17 |
Overview of Brooks Laboratories Limited
ISIN
INE650L01011
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
49,899
Market Cap
3,702,180,896
Last Dividend
0
Official Website
IPO Date
2011-09-05
DCF Diff
240.17
DCF
-114
Financial Ratios Every Investor Needs
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 82.56 Cr | 68.63 Cr | 13.92 Cr | 0.1686 | 0.00 Cr | 0.00 Cr | 3.34 Cr | -9.97 Cr | -3.72 | 5.82 Cr | -0.1207 |
2024-03-31 | 79.01 Cr | 72.92 Cr | 6.09 Cr | 0.0770 | 0.00 Cr | 4.37 Cr | 1.44 Cr | -19.59 Cr | -7.65 | 4.17 Cr | -0.2480 |
2023-03-31 | 63.20 Cr | 50.60 Cr | 12.60 Cr | 0.1994 | 0.00 Cr | 10.09 Cr | -33.40 Cr | -20.90 Cr | -8.38 | -29.17 Cr | -0.3307 |
2022-03-31 | 90.09 Cr | 75.80 Cr | 14.29 Cr | 0.1587 | 0.00 Cr | 8.84 Cr | -21.38 Cr | -19.31 Cr | -7.74 | -13.45 Cr | -0.2144 |
2021-03-31 | 77.07 Cr | 55.24 Cr | 21.83 Cr | 0.2832 | 0.00 Cr | 6.55 Cr | -6.57 Cr | -19.38 Cr | -7.77 | 1.25 Cr | -0.2514 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1.25 Cr | 123.69 Cr | 25.59 Cr | 98.1043 Cr | 7.58 Cr | 6.33 Cr | 9.20 Cr | 13.97 Cr | 0.00 Cr | 0.00 Cr | 73.69 Cr | 22.8441 Cr |
2024-03-31 | 0.13 Cr | 90.45 Cr | 24.86 Cr | 65.5853 Cr | 5.64 Cr | 5.52 Cr | 9.61 Cr | 13.60 Cr | 0.26 Cr | 0.00 Cr | 42.91 Cr | 23.0476 Cr |
2023-03-31 | 0.02 Cr | 109.60 Cr | 35.64 Cr | 73.9532 Cr | 6.51 Cr | 6.49 Cr | 11.30 Cr | 14.81 Cr | 2.60 Cr | 0.00 Cr | 64.19 Cr | 33.0213 Cr |
2022-03-31 | 2.61 Cr | 195.91 Cr | 61.59 Cr | 63.0508 Cr | 25.26 Cr | 22.65 Cr | 27.52 Cr | 124.49 Cr | 3.58 Cr | -5.37 Cr | 0.28 Cr | 48.8783 Cr |
2021-03-31 | 0.88 Cr | 162.08 Cr | 82.93 Cr | 79.1484 Cr | 31.38 Cr | 30.50 Cr | 23.60 Cr | 107.70 Cr | 14.56 Cr | 15.98 Cr | 0.33 Cr | 63.7142 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1.7623 Cr | -46.0409 Cr | 44.1965 Cr | -0.0971 Cr | 0.0000 Cr | 1.2480 Cr | -1.8594 Cr | -9.9670 Cr | 1.0213 Cr | 0.0000 Cr | 0.4060 Cr |
2024-03-31 | -9.6806 Cr | 0.1822 Cr | 9.6007 Cr | -10.1196 Cr | 0.1023 Cr | 0.1255 Cr | -0.4390 Cr | -19.5919 Cr | -0.8703 Cr | 0.0000 Cr | 1.6923 Cr |
2023-03-31 | -14.4906 Cr | 0.4948 Cr | 11.4140 Cr | -14.9581 Cr | -2.5818 Cr | 0.0232 Cr | -0.4675 Cr | -35.4251 Cr | -4.0322 Cr | 0.0000 Cr | 3.2860 Cr |
2022-03-31 | -37.4407 Cr | -24.9086 Cr | 64.0706 Cr | -65.0530 Cr | 1.7211 Cr | 2.6050 Cr | -27.6123 Cr | -23.8977 Cr | -7.2510 Cr | 0.0000 Cr | -3.9193 Cr |
2021-03-31 | 4.4587 Cr | -5.1296 Cr | 1.1589 Cr | -1.1551 Cr | 0.4880 Cr | 0.8839 Cr | -5.6138 Cr | -8.9933 Cr | 4.3813 Cr | 0.0000 Cr | -9.8282 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 23.32 Cr | 19.58 Cr | 3.74 Cr | 0.1602 | 1.15 Cr | -1.46 Cr | -0.54 | 2.16 Cr | -0.0625 |
2024-12-31 | 38.45 Cr | 25.06 Cr | 13.38 Cr | 0.3481 | 1.07 Cr | -4.57 Cr | -1.51 | -3.32 Cr | -0.1189 |
2024-09-30 | 20.79 Cr | 13.20 Cr | 7.59 Cr | 0.3653 | 1.08 Cr | -3.96 Cr | -1.51 | -3.21 Cr | -0.1906 |
2024-06-30 | 17.93 Cr | 12.31 Cr | 5.63 Cr | 0.3138 | -4.93 Cr | -2.41 Cr | -0.94 | -1.85 Cr | -0.1346 |
2024-03-31 | 17.72 Cr | 15.45 Cr | 2.27 Cr | 0.1281 | -0.08 Cr | -9.61 Cr | -3.77 | 1.03 Cr | -0.5420 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2025-03-31 | 1.25 Cr | 0.00 Cr | 1.25 Cr | 19.99 Cr | 9.20 Cr | 33.88 Cr | 13.97 Cr | 123.69 Cr | 25.59 Cr |
2024-12-31 | 0.00 Cr | 0.00 Cr | 0.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -59.21 Cr |
2024-09-30 | 0.17 Cr | 2.18 Cr | 2.35 Cr | 0.00 Cr | 9.48 Cr | 37.86 Cr | 14.55 Cr | 91.12 Cr | 31.92 Cr |
2024-06-30 | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | 0.69 Cr | 0.00 Cr | 0.00 Cr | -65.59 Cr |
2024-03-31 | 0.69 Cr | 2.33 Cr | 0.69 Cr | 16.32 Cr | 9.61 Cr | 31.05 Cr | 13.60 Cr | 90.45 Cr | 24.86 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | -4.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-09-30 | -3.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-06-30 | -2.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2024-03-31 | -9.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | -3.88 Cr | 0.87 Cr | 0.00 Cr | 0.00 Cr | 0.87 Cr | 1.37 Cr | 0.50 Cr | 0.00 Cr | 0.87 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
2020-02-11 | February 11, 20 | 1199:1000 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,666.50 | ₹3,998,400,120,000.00 | ₹3,297,857.00 |
Divi's Laboratories Limited | DIVISLAB | ₹6,856.50 | ₹1,820,188,198,500.00 | ₹385,715.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,416.70 | ₹1,156,365,031,500.00 | ₹1,549,634.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,282.00 | ₹1,066,726,226,680.00 | ₹1,851,147.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,002.50 | ₹1,008,745,575,000.00 | ₹925,425.00 |
Mankind Pharma Limited | MANKIND | ₹2,287.00 | ₹943,910,674,120.00 | ₹1,615,094.00 |
Lupin Limited | LUPIN | ₹1,960.90 | ₹895,533,225,500.00 | ₹1,091,918.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,132.50 | ₹657,758,265,000.00 | ₹961,788.00 |
Alkem Laboratories Limited | ALKEM | ₹4,849.00 | ₹579,770,685,000.00 | ₹220,010.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,754.30 | ₹495,065,214,300.00 | ₹447,756.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
Laurus Labs Limited | LAURUSLABS | ₹746.05 | ₹402,309,700,650.00 | ₹4,703,708.00 |
Cohance Lifesciences Limited | COHANCE | ₹960.30 | ₹367,379,097,782.00 | ₹345,784.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,371.90 | ₹348,056,517,600.00 | ₹193,130.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,502.70 | ₹312,617,262,400.00 | ₹222,556.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,677.40 | ₹272,542,274,600.00 | ₹662,501.00 |
Piramal Enterprises Limited | PEL | ₹1,168.80 | ₹264,941,246,400.00 | ₹632,587.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,645.60 | ₹256,810,690,400.00 | ₹802,162.00 |
Eris Lifesciences Limited | ERIS | ₹1,676.60 | ₹228,347,890,200.00 | ₹100,254.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,898.50 | ₹222,462,500,000.00 | ₹18,038.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹1,012.10 | ₹198,941,412,300.00 | ₹858,724.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹1,199.50 | ₹191,057,559,500.00 | ₹202,051.00 |
NATCO Pharma Limited | NATCOPHARM | ₹933.00 | ₹167,109,630,000.00 | ₹1,456,481.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹11,878.00 | ₹152,393,552,200.00 | ₹17,154.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,998.20 | ₹151,886,578,940.00 | ₹282,092.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹489.15 | ₹118,689,312,600.00 | ₹736,945.00 |
Procter & Gamble Health Limited | PGHL | ₹5,823.00 | ₹96,658,306,200.00 | ₹3,808.00 |
Shilpa Medicare Limited | SHILPAMED | ₹875.20 | ₹85,586,595,680.00 | ₹77,303.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹912.65 | ₹82,717,685,943.00 | ₹571,166.00 |
FDC Limited | FDC | ₹491.30 | ₹79,988,553,000.00 | ₹304,442.00 |
Strides Pharma Science Limited | STAR | ₹865.60 | ₹79,776,033,120.00 | ₹468,481.00 |
Suven Life Sciences Limited | SUVEN | ₹253.68 | ₹55,321,012,320.00 | ₹274,325.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹160.93 | ₹52,225,325,460.00 | ₹307,992.00 |
Innova Captab Limited | INNOVACAP | ₹844.30 | ₹48,315,008,399.00 | ₹48,142.00 |
Sequent Scientific Limited | SEQUENT | ₹187.53 | ₹46,939,696,650.00 | ₹413,364.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹469.65 | ₹42,864,955,500.00 | ₹280,048.00 |
Hikal Limited | HIKAL | ₹346.05 | ₹42,668,311,050.00 | ₹935,859.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,535.80 | ₹41,939,596,200.00 | ₹34,993.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹594.20 | ₹41,835,126,360.00 | ₹25,950.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹739.55 | ₹37,509,310,405.00 | ₹222,854.00 |
Gufic Biosciences Limited | GUFICBIO | ₹353.90 | ₹35,488,384,200.00 | ₹41,363.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹62.04 | ₹33,995,066,160.00 | ₹2,228,049.00 |
Alembic Limited | ALEMBICLTD | ₹123.03 | ₹31,591,889,337.00 | ₹1,124,853.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹652.35 | ₹31,412,609,550.00 | ₹200,236.00 |
Indoco Remedies Limited | INDOCO | ₹313.10 | ₹28,882,817,490.00 | ₹54,298.00 |
IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹96.76 | ₹28,401,672,520.00 | ₹1,730,977.00 |
Key Executives
Gender: male
Year Born: 1969
Gender: female
Year Born: 1993
Gender: male
Year Born: 1955
Gender: Not Specified
Year Born: 1964
Gender: male
Year Born: 1967
Gender: Not Specified
Year Born: 1964
Gender: male
Year Born: 1974
Gender: male
Year Born: 1991
FAQs about Brooks Laboratories Limited
The CEO is Mr. Prashant Rathi.
The current price is ₹125.68.
The range is ₹82-198.86.
The market capitalization is ₹370.22 crores.
The P/E ratio is -27.76.
The company operates in the Healthcare sector.
Overview of Brooks Laboratories Limited (ISIN: INE650L01011) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹370.22 crores and an average daily volume of 49,899 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.